Laggera pterodonta
Specifically for Bronchiolitis
0 up • 0 down
Why it works for Bronchiolitis:
Anti-inflammatory & antiviral actions (pre-clinical): Extracts and isolated compounds (notably the sesquiterpenoid pterodontic acid) show activity against respiratory viruses (e.g., influenza) and suppress inflammatory pathways in cell and animal models—mechanisms that are plausibly relevant to bronchiolitis. spandidos-publications.com
Traditional respiratory use + modern review: L. pterodonta has long been used for cough/colds/bronchitis in Chinese ethnomedicine. Recent scholarly reviews summarize constituents (flavonoids, terpenoids, phenolics) and reported antiviral/anti-inflammatory activities. ScienceDirect
How to use for Bronchiolitis:
- Hospital RCT regimen (Kunming, China): Infants 3–24 months with acute bronchiolitis received a Laggera pterodonta mixture or a control mixture three times per day for 5 days (total 15 doses). The abstract does not report the exact mL per dose. Europe PMC
- Commercial syrup label (灵丹草合剂 / “Lingdancao Heji”)—a preparation containing L. pterodonta—lists oral dosing 10–20 mL, 3–4×/day (general upper-respiratory indications; children only with physician guidance). Note: this is a product insert, not bronchiolitis-specific guidance. ypk.39.net
Because formulations (extract ratios, solvents, excipients) vary widely, do not extrapolate these doses across products. Discuss brand/formulation, dosing, and duration with a clinician experienced in pediatric herbal medicines
Scientific Evidence for Bronchiolitis:
Double-blind RCT (n=133; infants 3–24 months; three tertiary hospitals, Kunming): “Efficacy and safety of Laggera pterodonta in children 3–24 months with acute bronchiolitis,” Clinical Respiratory Journal 2015/2017 issue listing. The trial used a 5-day, TID regimen as adjunctive therapy during hospitalization. (Outcomes reported in the abstract/registries; full text access may be restricted.) Europe PMC
Trial registration: Chinese Clinical Trial Register ChiCTR-TRC-12002677 (prospectively registered). Chictr
Context from broader reviews: A 2017 systematic review of complementary/alternative medicines for bronchiolitis (multiple herbs/supplements across 904 infants) assessed length of stay as the primary outcome and noted overall moderate-quality evidence and need for better trials (it was not specific to Laggera but frames the evidence landscape). PLOS
Mechanistic/in-vivo adjuncts (non-bronchiolitis): Recent mouse and in-vitro studies detail anti-influenza actions of L. pterodonta preparations/constituents, supporting biological plausibility but not clinical effectiveness in RSV bronchiolitis. Cell
Specific Warnings for Bronchiolitis:
Not guideline-recommended: International pediatric guidelines (AAP, NICE, others) emphasize supportive care (oxygen for hypoxemia, hydration/feeding support) and generally discourage unproven drug/herbal therapies for bronchiolitis. Laggera is not in these guidelines. Pediatrics
Use only with pediatric oversight: Infants are highly vulnerable to dosing and excipient errors (e.g., alcohol, propylene glycol, honey). If a syrup is used, it should be a pediatric-appropriate product and dosing should be clinician-directed. (See label’s “children should use under physician guidance.”) ypk.39.net
Potential toxicity/“cold”/“toxic” herb designation in TCM: Traditional sources classify Herba Laggerae as cold and “toxic,” implying a narrow safety margin and the need for correct identification, preparation, and dosing. This is cautionary—modern toxicology data in infants are sparse. tcmwiki.com
Product variability: Essential-oil and extract composition differs by geography/processing, so potency and safety aren’t uniform across brands/batches. plant-ecology.com
Syrup-specific cautions: A common Chinese OTC syrup containing L. pterodonta advises avoid in diabetes, avoid concurrent “warming” tonics, and stop/seek care if no improvement within 3 days. These are label-level cautions, not clinical-trial–derived safety rules. ypk.39.net
Drug/herb interactions: Robust interaction data are lacking; given sesquiterpenoid bioactivity (e.g., acetylcholinesterase inhibition shown in vitro), use caution with drugs affecting neurologic or cholinergic tone. (Preclinical mechanistic signal only.) Frontiers
When to seek urgent care: Any infant with bronchiolitis who has poor feeding, apnea, cyanosis, or oxygen saturation below guideline thresholds requires prompt medical assessment; home remedies should never delay care. (See parameters in modern clinical guidance). sheffieldchildrens.nhs.uk
General Information (All Ailments)
What It Is
Laggera pterodonta is a perennial herb belonging to the Asteraceae (Compositae) family. It is widely distributed in tropical and subtropical regions of Africa and Asia, including parts of East and West Africa, China, and India. Traditionally, it has been used in folk medicine for its anti-inflammatory, antimicrobial, antiviral, antioxidant, and hepatoprotective properties.
The plant’s bioactive constituents include flavonoids, terpenoids, sesquiterpenes, and phenolic compounds, which contribute to its pharmacological activities. Extracts are typically prepared from the leaves, stems, and flowers, often in aqueous or ethanol-based solutions for medicinal use.
How It Works
The therapeutic effects of Laggera pterodonta are attributed to several biochemical and pharmacological mechanisms:
- Anti-inflammatory action: Certain sesquiterpenoids and flavonoids from the plant inhibit inflammatory mediators such as prostaglandins, nitric oxide, and cytokines (e.g., TNF-α, IL-6). This helps alleviate inflammation in conditions such as arthritis and respiratory infections.
- Antimicrobial and antiviral activity: Extracts demonstrate inhibitory effects against bacteria, fungi, and viruses, including hepatitis B virus and some respiratory pathogens. This is largely due to the plant’s phenolic and terpenoid compounds that disrupt microbial cell membranes or interfere with viral replication.
- Antioxidant properties: Flavonoids and polyphenols act as free radical scavengers, reducing oxidative stress that contributes to chronic diseases like liver disorders, cardiovascular disease, and cancer.
- Hepatoprotective effects: Animal studies suggest Laggera pterodonta can protect the liver from toxic damage by enhancing antioxidant enzyme activity (e.g., superoxide dismutase, catalase) and stabilizing hepatic cell membranes.
- Analgesic and antipyretic effects: The plant may help reduce pain and fever by inhibiting prostaglandin synthesis and modulating the body’s inflammatory response.
Why It’s Important
Laggera pterodonta holds significant importance in both traditional and modern medicine for several reasons:
- Traditional relevance: It has been used for centuries to treat ailments such as fevers, coughs, colds, wounds, and gastrointestinal disturbances, making it an integral part of ethnomedicine in many cultures.
- Potential for drug discovery: Due to its diverse bioactive compounds, Laggera pterodonta serves as a promising candidate for phytochemical and pharmacological research, potentially leading to the development of new therapeutic agents.
- Complementary therapy: In areas with limited access to conventional medicine, Laggera pterodonta offers an affordable and accessible natural remedy with scientifically supported benefits.
- Public health relevance: Given its antiviral and antimicrobial effects, it may play a role in combating infectious diseases—a crucial benefit in low-resource regions.
Considerations
While Laggera pterodonta shows promise, there are important factors to consider before its use:
- Safety and toxicity: Although generally considered safe in traditional doses, high or prolonged use may pose toxicity risks due to concentrated phytochemicals. Comprehensive toxicological studies are still limited.
- Standardization and dosage: Variations in preparation methods, plant origin, and extraction solvents can lead to inconsistent potency. Clinical standardization is essential for reliable therapeutic outcomes.
- Drug interactions: The plant’s bioactive compounds could interact with pharmaceuticals, especially those affecting liver enzymes or inflammation (e.g., NSAIDs, antivirals).
- Clinical evidence: Most evidence for Laggera pterodonta is preclinical (from animal or in vitro studies). Human clinical trials are limited, so its efficacy and safety profile in people are not fully established.
- Regulatory and quality control issues: Herbal products derived from Laggera pterodonta are not always subject to rigorous regulatory oversight, increasing the risk of adulteration or contamination.
Helps with these conditions
Laggera pterodonta is most effective for general wellness support with emerging research . The effectiveness varies by condition based on clinical evidence and user experiences.
Detailed Information by Condition
Bronchiolitis
Anti-inflammatory & antiviral actions (pre-clinical): Extracts and isolated compounds (notably the sesquiterpenoid pterodontic acid) show activity...
Community Discussion
Share results, tips, and questions about Laggera pterodonta.
Loading discussion...
No comments yet. Be the first to start the conversation!
Discussion for Bronchiolitis
Talk specifically about using Laggera pterodonta for Bronchiolitis.
Loading discussion...
No comments yet. Be the first to start the conversation!
Remedy Statistics
Helps With These Conditions
Recommended Products
No recommended products added yet.